Genscript Biotech Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Genscript Biotech kazanç ve gelirin sırasıyla yıllık 97.9% ve 5.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 97.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.3% olacağı tahmin edilmektedir.
Anahtar bilgiler
97.9%
Kazanç büyüme oranı
97.35%
EPS büyüme oranı
| Life Sciences kazanç büyümesi | 41.0% |
| Gelir büyüme oranı | 5.1% |
| Gelecekteki özkaynak getirisi | 8.33% |
| Analist kapsamı | Good |
| Son güncelleme | 25 Apr 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Anlatı Güncellemesi • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Anlatı Güncellemesi • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Yeni Anlatı • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Anlatı Güncellemesi • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.Anlatı Güncellemesi • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.Anlatı Güncellemesi • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Analiz Makalesi • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Analiz Makalesi • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...Analiz Makalesi • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Analiz Makalesi • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Analiz Makalesi • Jul 29
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...Analiz Makalesi • Jul 24
At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it saw a significant share price rise...Yeni Anlatı • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analiz Makalesi • May 14
Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Apr 07
Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Genscript Biotech Corporation ( HKG:1548 ) shares have retraced a considerable 27% in the last month, reversing a fair...Analiz Makalesi • Feb 12
Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 27% after a shaky period...Analiz Makalesi • Jan 20
Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Genscript Biotech is HK$19.29 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Nov 19
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
It's not a stretch to say that Genscript Biotech Corporation's ( HKG:1548 ) price-to-sales (or "P/S") ratio of 2.9x...Analiz Makalesi • Oct 01
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Sep 16
What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it received a lot of attention from a...Analiz Makalesi • Aug 02
After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 44% after a shaky period...Analiz Makalesi • Jun 05
Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Genscript Biotech Corporation ( HKG:1548 ) share price has dived 28% in the...Analiz Makalesi • May 10
A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Key Insights The projected fair value for Genscript Biotech is HK$14.11 based on 2 Stage Free Cash Flow to Equity With...Analiz Makalesi • Apr 13
Is Genscript Biotech (HKG:1548) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analiz Makalesi • Mar 13
Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Genscript Biotech Corporation ( HKG:1548 ) shareholders are no doubt pleased to see that the share price has bounced...Analiz Makalesi • Jan 26
Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Genscript Biotech Corporation ( HKG:1548 ) shareholders that were waiting for something to happen have been dealt a...Analiz Makalesi • Nov 21
Is Genscript Biotech (HKG:1548) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Aug 22
Is Genscript Biotech (HKG:1548) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Apr 04
Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook
The analysts covering Genscript Biotech Corporation ( HKG:1548 ) delivered a dose of negativity to shareholders today...Analiz Makalesi • Apr 03
Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report
It's been a mediocre week for Genscript Biotech Corporation ( HKG:1548 ) shareholders, with the stock dropping 10% to...Analiz Makalesi • Apr 02
Is Genscript Biotech (HKG:1548) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 1,045 | 360 | 239 | 388 | 6 |
| 12/31/2027 | 931 | 219 | 134 | 133 | 7 |
| 12/31/2026 | 816 | 75 | 127 | 176 | 7 |
| 12/31/2025 | 960 | -533 | 242 | 326 | N/A |
| 9/30/2025 | 894 | -264 | 184 | 277 | N/A |
| 6/30/2025 | 828 | 5 | 126 | 228 | N/A |
| 3/31/2025 | 711 | -31 | 2 | 152 | N/A |
| 12/31/2024 | 594 | -67 | -121 | 76 | N/A |
| 6/30/2024 | 454 | 419 | -276 | -20 | N/A |
| 3/31/2024 | 507 | 421 | -410 | -153 | N/A |
| 12/31/2023 | 560 | 423 | -543 | -287 | N/A |
| 9/30/2023 | 773 | -140 | -506 | -266 | N/A |
| 6/30/2023 | 707 | -185 | -523 | -245 | N/A |
| 3/31/2023 | 667 | -206 | -431 | -183 | N/A |
| 12/31/2022 | 626 | -227 | -339 | -120 | N/A |
| 9/30/2022 | 598 | -315 | -321 | -142 | N/A |
| 6/30/2022 | 570 | -403 | -304 | -163 | N/A |
| 3/31/2022 | 530 | -381 | -289 | -150 | N/A |
| 12/31/2021 | 490 | -359 | -274 | -137 | N/A |
| 9/30/2021 | 483 | -265 | -265 | -127 | N/A |
| 6/30/2021 | 454 | -183 | -256 | -118 | N/A |
| 3/31/2021 | 422 | -194 | -268 | -134 | N/A |
| 12/31/2020 | 391 | -205 | -279 | -151 | N/A |
| 9/30/2020 | 354 | -194 | -171 | -48 | N/A |
| 6/30/2020 | 318 | -183 | -64 | 54 | N/A |
| 3/31/2020 | 296 | -140 | -103 | 12 | N/A |
| 12/31/2019 | 273 | -97 | -142 | -30 | N/A |
| 9/30/2019 | 257 | -59 | N/A | -116 | N/A |
| 6/30/2019 | 241 | -22 | N/A | -202 | N/A |
| 3/31/2019 | 236 | 0 | N/A | 53 | N/A |
| 12/31/2018 | 231 | 21 | N/A | 308 | N/A |
| 9/30/2018 | 216 | 24 | N/A | 338 | N/A |
| 6/30/2018 | 201 | 27 | N/A | 369 | N/A |
| 3/31/2018 | 177 | 26 | N/A | 195 | N/A |
| 12/31/2017 | 153 | 26 | N/A | 21 | N/A |
| 9/30/2017 | 139 | 27 | N/A | 24 | N/A |
| 6/30/2017 | 125 | 28 | N/A | 27 | N/A |
| 3/31/2017 | 120 | 27 | N/A | 30 | N/A |
| 12/31/2016 | 115 | 26 | N/A | 33 | N/A |
| 9/30/2016 | 107 | 26 | N/A | 29 | N/A |
| 6/30/2016 | 99 | 25 | N/A | 25 | N/A |
| 3/31/2016 | 93 | 21 | N/A | 22 | N/A |
| 12/31/2015 | 87 | 18 | N/A | 20 | N/A |
| 9/30/2015 | 82 | 13 | N/A | 18 | N/A |
| 6/30/2015 | 78 | 8 | N/A | 16 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 1548 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: 1548 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: 1548 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: 1548 şirketinin gelirinin (yıllık 5.1% ) Hong Kong pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 1548 şirketinin gelirinin (yıllık 5.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 1548 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.3 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 16:50 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Genscript Biotech Corporation 12 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |